...
首页> 外文期刊>Washington Drug Letter >Snowe Seeks 'Middle Ground' In Biotech Funding Debate
【24h】

Snowe Seeks 'Middle Ground' In Biotech Funding Debate

机译:斯诺在生物技术融资辩论中寻求“中间立场”

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Senate Republicans are working on a compromise to allow more venture capital-backed biotech firms to be eligible for federal research funding. Sen. Olympia Snowe (R-Maine), the chairwoman of the Small Business and Entrepreneurship Committee, will be working with other Republican lawmakers and the Biotechnology Information Organization (BIO) to decide how to allow biotech firms with venture capital backing to receive federal funds reserved for small businesses. At issue is R&D funding awarded under the Small Business Administration's Small Business Innovation Research Program (SBIR), which accounts for approximately $2 billion in grants annually.
机译:参议院共和党人正在做出折衷方案,以允许更多的风险资本支持的生物技术公司有资格获得联邦研究资金。小型企业和创业委员会主席奥林匹亚·斯诺(R-Maine)参议员将与其他共和党议员和生物技术信息组织(BIO)合作,决定如何允许具有风险资本支持的生物技术公司获得联邦资金保留给小型企业。争论的焦点是小型企业管理局的小型企业创新研究计划(SBIR)授予的研发资金,该计划每年约有20亿美元的拨款。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号